Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Functional MRI for anticancer therapy assessment.

A R Padhani1

  • 1Paul Strickland Scanner Centre, Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK. anwar@padhani.fsnet.co.uk

European Journal of Cancer (Oxford, England : 1990)
|October 22, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Agentic AI for Prostate Cancer: A Vision for Multimodal Clinical Intelligence.

European urology oncology·2026
Same author

Audit of cancer yields after prostate MRI using both the PI-RADS version 2 and Likert scoring systems.

Clinical radiology·2022
Same author

A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk.

Prostate cancer and prostatic diseases·2020
Same author

Sacral Insufficiency Fracture Following Pelvic Radiotherapy in Gynaecological Malignancies: Development of a Predictive Model.

Clinical oncology (Royal College of Radiologists (Great Britain))·2020
Same author

Diagnostic yields in patients with suspected prostate cancer undergoing MRI as the first-line investigation in routine practice.

Clinical radiology·2020
Same author

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same journal

The clinical relevance of regional lymph node microarchitecture in oesophageal cancer patients - Results from the UK MRC OE02 trial.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Early-onset colorectal cancer across Europe: Burden, mechanisms, and health-system implications.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinical urgency of incidental findings in the first year of the 4-IN-THE-LUNG-RUN lung cancer screening program.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
See all related articles

Functional magnetic resonance imaging (fMRI) offers new ways to evaluate cancer drug effectiveness. This technique helps assess new cancer therapies by measuring drug effects, speeding up clinical trials.

Area of Science:

  • Oncology
  • Medical Imaging
  • Pharmacology

Background:

  • Cancer therapy is shifting towards targeted treatments, moving away from traditional cytotoxic drugs.
  • Newer cancer therapies are often cytostatic, making tumor shrinkage an inadequate measure of efficacy.
  • There's a critical need for surrogate endpoints to accelerate the evaluation of drug combinations in clinical trials.

Purpose of the Study:

  • To review the emerging role of functional magnetic resonance imaging (fMRI) in cancer drug development.
  • To explore fMRI's potential for pharmacodynamic evaluation of novel and existing cancer therapeutics.
  • To discuss the integration of fMRI into clinical trial protocols.

Main Methods:

  • Focus on dynamic contrast-enhanced MRI (DCE-MRI) as a key functional MRI technique.

Related Experiment Videos

  • Review of DCE-MRI applications in evaluating anti-angiogenic and anti-vascular cancer agents.
  • Discussion of the prerequisites for implementing functional MRI in clinical settings.

    • Main Results:

    • Functional MRI, particularly DCE-MRI, shows promise as a surrogate endpoint for cancer drug efficacy.
    • DCE-MRI is actively used in human trials to assess the impact of anti-angiogenic and anti-vascular therapies.
    • The review highlights the technical and clinical considerations for adopting fMRI in cancer drug evaluation.

    Conclusions:

    • Functional MRI techniques are crucial for evaluating novel cancer therapeutics, especially cytostatic agents.
    • DCE-MRI can serve as a valuable pharmacodynamic tool, potentially accelerating drug development timelines.
    • Standardizing functional MRI protocols is essential for its widespread adoption in clinical cancer research.